UnitedHealth Group (UNH) Q4 2025 earnings review
The Great Reset: Earnings Collapse as Management Clears the Decks
UnitedHealth Group's Q4 2025 results mark the nadir of a disastrous year. While full-year revenue grew 12% to $447.6B, the earnings power of the company evaporated due to unprecedented medical costs and operational failures. Adjusted EPS for FY25 fell to $16.35, a staggering 41% drop from $27.66 in FY24. Q4 alone saw adjusted Net Margin compress to 1.4% (vs 5.9% in 24Q4) as the Medical Care Ratio (MCR) blew out to 91.5%. Management has initiated a 'kitchen sink' quarter, taking $2.8B in pre-tax charges to exit unprofitable businesses. The 2026 guidance implies a painful stabilization period: revenue will actually *shrink* by ~2% as UNH sheds millions of unprofitable members to restore margins.
🐂 Bull Case
Management is prioritizing margins over growth for 2026. By pricing for a 10% medical cost trend and exiting unprofitable commercial/MA plans, they are accepting revenue contraction to rebuild the bottom line. The 2026 floor is set at $17.75 EPS.
Amidst the chaos in Health and Insurance, Optum Rx remains a fortress. Revenue grew 16% YoY in FY25 to $154.7B, and adjusted operating earnings grew to $6.1B (+5%). It remains a stable cash generator.
🐻 Bear Case
Optum Health, once the growth engine, swung to an adjusted operating loss of $219M in Q4 (vs. +$1.8B profit in 24Q4). The transition to value-based care in a high-utilization environment has failed spectacularly so far, requiring a complete operational overhaul.
The adjusted MCR hit 91.5% in Q4. Until utilization trends stabilize, the company is at the mercy of medical inflation. Guidance assumes improvement to ~88.8% in 2026, but forecasting credibility is currently low.
⚖️ Verdict: 🔴🔴
Bearish. This is a broken growth story in the midst of urgent repair. While the valuation has likely reset, the operational damage—specifically at Optum Health—is deep. 2026 is a 'fix-it' year with shrinking revenue, making capital appreciation unlikely until 2027 visibility improves.
Key Themes
Optum Health Profitability Collapse
Reversing. The deterioration in Optum Health is severe. In Q4, the segment reported an Adjusted Operating Loss of $219M, a shocking reversal from a $1.8B profit a year ago. Management cited reimbursement pressure, Medicare funding reductions, and elevated medical costs. This segment was previously the company's highest-multiple growth driver; it is now a drag on results.
Medical Care Ratio Blowout
Accelerating (Bad). The Adjusted Medical Care Ratio (MCR) for Q4 2025 reached 91.5% (calculated from adjusted figures), up significantly from ~85% in the prior year. FY25 MCR settled at 88.9%. This indicates that pricing completely failed to keep pace with utilization trends, specifically in Medicare Advantage and Medicaid. The 2026 guidance of 88.8% implies only marginal improvement, suggesting high costs are structural.
Intentional Shrinkage: The 'Right-Sizing' Strategy
Reversing. UNH is deliberately shrinking to restore profitability. Management explicitly stated they are exiting markets and products, leading to a projected ~1 million member decline in Medicare Advantage and a 2/3 reduction in ACA enrollment for 2026. This drives the projected 2% revenue decline in 2026 guidance. It is a necessary but painful pivot from their historical 'growth at all costs' narrative.
The $2.8 Billion 'Kitchen Sink' Charge
Management took a massive $2.8B pre-tax charge ($1.78 EPS impact) in Q4. This covers cyberattack final costs ($799M), net portfolio divestitures ($442M), and restructuring ($2.5B). While termed 'non-recurring,' the sheer size highlights the operational disarray faced in 2025. This clears the decks for 2026 but severely impacts GAAP equity.
Medicaid Margin Compression
Medicaid remains a drag. Management flagged that state funding has not kept pace with the acuity of the remaining pool post-redeterminations. They expect 2026 to be the 'trough' for Medicaid performance, with margins declining further before recovering over an 18-24 month period. This sector is currently a headwind rather than a stabilizer.
Other KPIs
Collapsing. Down from 4.1% in 24Q4. The insurance business barely broke even on an operating basis in the quarter due to the mismatch between premiums and claims. The 2026 target is ~3.2%, which requires flawless execution on the repricing strategy.
Accelerating. Up 16% YoY. Optum Rx continues to perform well driven by pharmacy services growth and new client volumes. It is effectively subsidizing the losses in the care delivery business right now.
Decelerating. Down from $24.2B in 2024. While still 1.5x Net Income (due to depressed income), the raw cash generation power has diminished. 2026 guidance calls for >$18.0B, indicating no immediate bounce back to 2023 levels ($29B).
Guidance
Reversing. Guidance implies a ~2% decline vs 2025's $447.6B. This is the first time in recent history UNH has guided for a revenue contraction, reflecting the divestiture of $10B+ in non-core revenue and member exits.
Stable/Low Growth. Represents an 8.5% increase off the depressed 2025 base of $16.35, but remains far below the $27+ earnings power seen in 2023-2024. This confirms 2026 is a stabilization year, not a recovery year.
Stable. The guide is essentially flat vs the 2025 adjusted finish of 88.9%. This admits that the structural cost increase is permanent and UNH is relying on premium hikes to cover it, rather than expecting utilization to drop back to historical norms.
Accelerating. Targets improvement from 3.5% in 2025. This relies heavily on eliminating the losses in Optum Health and continuing Optum Rx performance. Excluding loss contracts, they see ~4.9%.
Key Questions
Optum Health Breakeven Timeline
Optum Health swung to a $219M adjusted loss in Q4. Specifically, how much of the 2026 improvement relies on 'addition by subtraction' (exiting lives) versus actual clinical margin improvement on retained members?
Pricing Adequacy for 2026
You are guiding MCR to ~88.8% for 2026, consistent with 2025. Given the massive miss in forecasting 2025 utilization, what specific buffers have you built into the 2026 pricing to ensure you don't miss trend again?
Debt and Buyback Strategy
With the stock significantly depressed, but cash flow guided down to $18B and a focus on deleveraging (targeting 40% debt-to-capital), when can investors realistically expect share repurchases to resume?